Last updated: 2026-09-16 09:46:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Veru Inc. (VERU) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.33, with a market capitalisation of $39.90M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.05 to $7.33. This page covers its latest market performance, valuation, price trends and company information.
$39.90M | |
$2.40 | |
$245.70 | |
$2.05 | |
$2.34 | |
435.00 | |
285.17K | |
-- | |
$7.33 | |
$2.05 | |
-- | |
-- |
Veru Inc. (VERU) is trading at $2.33 in pre-market trading as of 2026-09-16 09:27:00, down 0.60% ($0.01) from the previous close of $2.34
Pre-market trading shows how investors are pricing VERU before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Veru Inc. (VERU) moved from $2.64 to $2.33, representing a decline of 11.89% ($0.31).
The stock traded between $2.29 and $2.85 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 359.57 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 5.2%
VERU is currently trading at $2.33, placing it 5.2% of the way from its 52-week low of $2.05 to its 52-week high of $7.33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Veru Inc. (VERU) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.